Page 7 - Dr Reddy's

Dr Reddy's re-draws new drug plan

Unlike in the past, when it tried to produce its own molecule, this time the company is licensing these from abroad

Dr Reddy's launches psoriasis treatment spray

A prescription topical steroid approved by the USFDA in February, 2016

Dr Reddy's: Weak Q4, uncertainties remain

Venezuelan adjustments hit results. Plants under US scanner; slow India growth; hence, prospects subdued

Dr Reddy's Q4 net down 85% at Rs 75 cr

Provisioning to write down receivables from Venezuela, higher tax expenses and decrease in revenues impacted the company's profits

Dr Reddy's signs US licensing agreement with XenoPort

The drug major will pay an upfront fee of $50 million (Rs 335 crore) to XenoPort